Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19.

No differences between the two antivirals were observed. In this real-life setting, the early use of both of the oral antivirals helped limit composite outcome at 30 days among subjects who were at high risk of disease progression.